Pinealon
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Pinealon is a synthetic tripeptide — a short chain of three amino acids (glutamic acid, aspartic acid, and arginine, often abbreviated Glu-Asp-Arg or “EDR”). It was developed as part of the Khavinson peptide-bioregulator research program in Saint Petersburg, a body of work focused on short peptides thought to influence gene expression.
It is most often discussed in the context of brain health, where it is studied for possible neuroprotective effects, memory support, and circadian or sleep-quality regulation. Its small size is frequently cited as the reason researchers are interested in how it may reach and act within neural tissue.
Most of the evidence to date comes from cell-culture and animal models. Human clinical data is limited, and Pinealon is not approved by any major regulator for therapeutic use.
How it works
Pinealon is classified as a peptide bioregulator, a group of short peptides hypothesized to interact directly with DNA and modulate the expression of specific genes. In preclinical studies it has been reported to influence genes and proteins tied to antioxidant defense, neuronal survival, and the regulation of programmed cell death (apoptosis).
A recurring theme in the research is reduction of oxidative stress: laboratory studies describe dose-dependent decreases in reactive oxygen species in neurons and other cell types exposed to Pinealon. Some authors also link it to circadian signaling and neuronal resilience, though the precise mechanism in humans is not established.
Reported benefits
- Neuroprotection and reduced oxidative stress in neurons (preclinical data)
- Support for memory and cognitive function (largely animal studies, limited human reports)
- Improved sleep quality and circadian regulation (emerging, not well established)
- Support for neuronal survival under stress conditions (cell-culture data)
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous human trials are lacking, the long-term safety profile of Pinealon is not well characterized. Much of what is known comes from short-term preclinical work, so conclusions about tolerability in people remain preliminary.
Product purity and identity vary widely in the research-chemical market, which adds further uncertainty for anyone reviewing this compound. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Pinealon?
A synthetic tripeptide made of three amino acids (glutamic acid, aspartic acid, and arginine — Glu-Asp-Arg), developed within the Khavinson peptide-bioregulator research program and studied mainly for neuroprotection and cognitive support.
Is Pinealon FDA-approved?
No. Pinealon is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
Why is Pinealon also called the EDR peptide?
EDR refers to the single-letter codes of its three amino acids (E = glutamic acid, D = aspartic acid, R = arginine). The two names describe the same molecule.
What kind of evidence exists for Pinealon?
The available evidence is largely preclinical — cell-culture and animal studies — with only limited human data. It should be considered an emerging research compound rather than an established therapy.
References
Related compounds
Delta Sleep Inducing Peptide. Promotes deep, restorative sleep. May help normalize sleep patterns.
Sleep and longevity blend combining Delta Sleep-Inducing Peptide (DSIP), studied for deepening slow-wave sleep, with Epithalon, a pineal-modulating tetrapeptide studied for circadian and anti-aging effects. Sold as a combo vial.
An oral Khavinson peptide bioregulator (peptide complex A-5) derived from calf brain tissue, targeting the central nervous system. Taken in capsule courses to support cognitive function and neuronal health.